Gilead posts long-term data showing sustained liver marker normalization with Livdelzi
Gilead Sciences (NASDAQ:GILD) released new results from a post hoc analysis of its open-label Phase 3 ASSURE study, demonstrating that its approved drug Livdelzi (seladelpar) achieved high and sustained rates of normalization in a key biomarker of liver disease progression.



_1407476_640x360_2501505091693-640x360.webp&w=3840&q=75)


_1407456_640x360_2501504067584-640x360.webp&w=3840&q=75)
_1407422_640x360_2501497411628-640x360.webp&w=3840&q=75)
_1407420_640x360_2501496387756-640x360.webp&w=3840&q=75)


